HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sharkey, R. M. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Sharkey, R. M. Articles by Goldenberg, D. M.

Radioimmunotherapy of Non-Hodgkin’s Lymphoma with ⁹⁰Y-DOTA Humanized Anti-CD22 IgG (⁹⁰Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?

¹ Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
² Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
³ Roswell Park Cancer Center, Buffalo, New York
⁴ University Hospital, René Gauducheau Cancer Center, Nantes, France
⁵ Fox Chase Cancer Center, Philadelphia, Pennsylvania
⁶ University of Oklahoma Health Sciences Center, Department of Radiological Sciences, Oklahoma City, Oklahoma

A DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid)-conjugated, ¹¹¹In- and ⁹⁰Y-labeled humanized antibody to CD22, epratuzumab, was studied in patients with non-Hodgkin’s lymphoma (NHL) to assess biodistribution and tumor targeting, pharmacokinetics, dosimetry, and anti-antibody response. Of particular interest was to evaluate whether pretherapy targeting and tumor dosimetry could predict therapeutic responses. Methods: Patients received a pretherapy imaging study with ¹¹¹In-DOTA-epratuzumab IgG (0.75 mg/kg), followed about 1 wk later with ⁹⁰Y-DOTA-epratuzumab starting at a dose level of 0.185 GBq/m² (5 mCi/m²) in patients who had prior high-dose chemotherapy (group 2), and at 0.370 GBq/m² in patients who did not have a prior transplant (group 1), with escalation in 0.185-GBq/m² increments. Results: The effective blood half-life for ¹¹¹In-DOTA epratuzumab was 36.1 ± 7.9 h (n = 25) compared with 35.2 ± 7.0 h for ⁹⁰Y-DOTA-epratuzumab (n = 22). The whole-body half-life for ⁹⁰Y-DOTA-epratuzumab estimated from ¹¹¹In-DOTA-epratuzumab scintigraphy was 58.3 ± 4.7 h (n = 20), with urine collection confirming the loss of between 2.2% and 15.9% of the injected activity over 3 d (n = 3). One-hundred sixteen of 165 CT-confirmed lesions were visualized with ¹¹¹In-DOTA-epratuzumab. Radiation-absorbed doses to liver, lungs, and kidneys averaged 0.55 ± 0.13 (n = 17), 0.28 ± 0.06 (n = 17), and 0.38 ± 0.07 mGy/MBq (n = 10), respectively, with 0.14 ± 0.02 and 0.23 ± 0.04 mGy/MBq delivered to the whole-body and red marrow, respectively. Tumor doses (n = 14 lesions in 10 patients) ranged from 1.0 to as much as 83 mGy/MBq for a 0.5-g lesion (median, 7.15 mGy/MBq). Group 2 patients were more likely to experience significant hematologic toxicities, but doses of up to 0.370 GBq/m² of ⁹⁰Y-DOTA-epratuzumab were tolerated with standard support measures, whereas patients in group 1 tolerated doses of up to 0.740 GBq/m² with the potential for further escalation. Anti-tumor effects were seen in both indolent and aggressive NHL. The data also suggest that anti-tumor responses of potentially equal magnitude can occur irrespective of tumor targeting and tumor size. Hence, tumor response did not correlate with the radiation dose delivered or with the tumor being visualized by external imaging. An anti-antibody response to epratuzumab was detected by an enzyme-linked immunosorbent assay in only 2 of 16 patients. Conclusion: These results suggest that ⁹⁰Y-DOTA-epratuzmab is a promising agent for the treatment of NHL and warrants further study. There was evidence suggesting that in this system, factors other than tumor radiation dose and targeting may be involved in the success of radioimmunotherapy.

Key Words: radioimmunotherapy • non-Hodgkin’s lymphoma • anti-CD22 • ⁹⁰Y-epratuzumab • antibody targeting

This article has been cited by other articles:

				C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography Haematologica, March 1, 2008; 93(3): 390 - 397. [Abstract] [Full Text] [PDF]

				P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s. [Abstract] [Full Text] [PDF]

				H. K. Tan, R. W. Wassenaar, and W. Zeng Collimator Selection, Acquisition Speed, and Visual Assessment of 131I-Tositumomab Biodistribution in a Phantom Model J. Nucl. Med. Technol., December 1, 2006; 34(4): 224 - 227. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF]

				J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, et al. Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma J. Clin. Oncol., August 1, 2005; 23(22): 5044 - 5051. [Abstract] [Full Text] [PDF]

				O. Linden, C. Hindorf, E. Cavallin-Stahl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, and J. Tennvall Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clin. Cancer Res., July 15, 2005; 11(14): 5215 - 5222. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg and R. M. Sharkey Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited J. Nucl. Med., February 1, 2005; 46(2): 383 - 384. [Full Text] [PDF]

				G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				S. Modak and N.-K. V. Cheung Antibody-Based Targeted Radiation to Pediatric Tumors J. Nucl. Med., January 1, 2005; 46(1_suppl): 157S - 163S. [Abstract] [Full Text] [PDF]

				J. F. DiJoseph, M. E. Goad, M. M. Dougher, E. R. Boghaert, A. Kunz, P. R. Hamann, and N. K. Damle Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma Clin. Cancer Res., December 15, 2004; 10(24): 8620 - 8629. [Abstract] [Full Text] [PDF]

				E. J. Postema and K. E. Britton Dosimetry and Radioimmunotherapy of Non-Hodgkin's Lymphoma J. Nucl. Med., December 1, 2004; 45(12): 2126 - 2127. [Full Text] [PDF]

				K. F. Koral, K. Zasadny, R. L. Wahl, and R. M. Sharkey Bias Reduction in Correlation of Radiation-Absorbed Dose with Response J. Nucl. Med., July 1, 2004; 45(7): 1271 - 1272. [Full Text] [PDF]